| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2005-11-16 15:48:42 UTC |
|---|
| Updated at | 2020-11-24 22:18:01 UTC |
|---|
| NP-MRD ID | NP0000752 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Ureidopropionic acid |
|---|
| Description | Ureidopropionic acid is an intermediate in the metabolism of uracil. More specifically it is a breakdown product of dihydrouracil and is produced by the enzyme dihydropyrimidase. It is further decomposed to beta-alanine via the enzyme beta-ureidopropionase. Ureidopropionic acid is essentially a urea derivative of beta-alanine. High levels of Ureidopropionic acid are found in individuals with beta-ureidopropionase (UP) deficiency [PMID: 11675655 ]. Enzyme deficiencies in pyrimidine metabolism are associated with a risk for severe toxicity against the antineoplastic agent 5-fluorouracil. |
|---|
| Structure | InChI=1S/C4H8N2O3/c5-4(9)6-2-1-3(7)8/h1-2H2,(H,7,8)(H3,5,6,9) |
|---|
| Synonyms | | Value | Source |
|---|
| 3-[(Aminocarbonyl)amino]propanoic acid | ChEBI | | 3-Ureidopropanoate | ChEBI | | 3-Ureidopropanoic acid | ChEBI | | 3-Ureidopropionate | ChEBI | | 3-Ureidopropionic acid | ChEBI | | beta-Ureidopropionic acid | ChEBI | | N-(AMINOCARBONYL)-BETA-alanine | ChEBI | | Ureidopropanoic acid | ChEBI | | N-Carbamoyl-beta-alanine | Kegg | | 3-[(Aminocarbonyl)amino]propanoate | Generator | | b-Ureidopropionate | Generator | | b-Ureidopropionic acid | Generator | | beta-Ureidopropionate | Generator | | Β-ureidopropionate | Generator | | Β-ureidopropionic acid | Generator | | N-(AMINOCARBONYL)-b-alanine | Generator | | N-(AMINOCARBONYL)-β-alanine | Generator | | Ureidopropanoate | Generator | | N-Carbamoyl-b-alanine | Generator | | N-Carbamoyl-β-alanine | Generator | | Ureidopropionate | Generator | | 3-(carbamoylamino)Propanoate | HMDB | | 3-(carbamoylamino)Propanoic acid | HMDB | | 3-ureido-Propionate | HMDB | | Carbamoyl-b-ala-OH | HMDB | | Carbamoyl-beta-ala-OH | HMDB | | N-(Aminocarbonyl)-'b-alanine | HMDB | | N-Carbamyl-b-alanine | HMDB | | N-Carbamyl-beta-alanine | HMDB | | Ion(-1) OF N-carbamoyl-beta-alanine | MeSH, HMDB | | Carbamoyl-beta-alanine | HMDB | | Carbamoyl-β-alanine | HMDB | | Carbamyl beta-alanine | HMDB | | Carbamyl β-alanine | HMDB | | beta-Ureidopropanoic acid | HMDB | | β-Ureidopropanoic acid | HMDB |
|
|---|
| Chemical Formula | C4H8N2O3 |
|---|
| Average Mass | 132.1179 Da |
|---|
| Monoisotopic Mass | 132.05349 Da |
|---|
| IUPAC Name | 3-(carbamoylamino)propanoic acid |
|---|
| Traditional Name | ureidopropionic acid |
|---|
| CAS Registry Number | 462-88-4 |
|---|
| SMILES | OC(=O)CCNC(O)=N |
|---|
| InChI Identifier | InChI=1S/C4H8N2O3/c5-4(9)6-2-1-3(7)8/h1-2H2,(H,7,8)(H3,5,6,9) |
|---|
| InChI Key | JSJWCHRYRHKBBW-UHFFFAOYSA-N |
|---|
| Experimental Spectra |
|---|
|
| | Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Predicted Spectra |
|---|
|
| Not Available | | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as ureas. Ureas are compounds containing two amine groups joined by a carbonyl (C=O) functional group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Organic carbonic acids and derivatives |
|---|
| Sub Class | Ureas |
|---|
| Direct Parent | Ureas |
|---|
| Alternative Parents | |
|---|
| Substituents | - Urea
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | 170 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 20.9 mg/mL | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Moolenaar SH, Gohlich-Ratmann G, Engelke UF, Spraul M, Humpfer E, Dvortsak P, Voit T, Hoffmann GF, Brautigam C, van Kuilenburg AB, van Gennip A, Vreken P, Wevers RA: beta-Ureidopropionase deficiency: a novel inborn error of metabolism discovered using NMR spectroscopy on urine. Magn Reson Med. 2001 Nov;46(5):1014-7. [PubMed:11675655 ]
- Sparidans RW, Bosch TM, Jorger M, Schellens JH, Beijnen JH: Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jul 24;839(1-2):45-53. Epub 2006 Feb 28. [PubMed:16513432 ]
- Ito S, Kawamura T, Inada M, Inoue Y, Hirao Y, Koga T, Kunizaki J, Shimizu T, Sato H: Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. Br J Clin Pharmacol. 2005 Dec;60(6):584-93. [PubMed:16305582 ]
- Hofmann U, Schwab M, Seefried S, Marx C, Zanger UM, Eichelbaum M, Murdter TE: Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):371-80. [PubMed:12798197 ]
- Malet-Martino MC, Armand JP, Lopez A, Bernadou J, Beteille JP, Bon M, Martino R: Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry. Cancer Res. 1986 Apr;46(4 Pt 2):2105-12. [PubMed:2936452 ]
- Desmoulin F, Gilard V, Malet-Martino M, Martino R: Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine. Drug Metab Dispos. 2002 Nov;30(11):1221-9. [PubMed:12386128 ]
|
|---|